Last reviewed · How we verify
CHLORMADINONE ACETATE
CHLORMADINONE ACETATE is a drug. It is currently FDA-approved.
Chlormadinone acetate is a medication used in combination with ethinylestradiol for conditions such as polycystic ovary syndrome and venous thromboembolism, and has also been studied for its effects on body weight and pharmacogenomics. It is typically administered in combination with ethinylestradiol, often in a dosage of 30 mcg ethinylestradiol/2 mg chlormadinone acetate.
At a glance
| Generic name | CHLORMADINONE ACETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RIVET - Retrospective Cohort Study on the Risk of Venous Thromboembolism
- Comparison of Body Weight Change During Contraception With Belara and Yasmin (PHASE4)
- Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile (PHASE4)
- Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHLORMADINONE ACETATE CI brief — competitive landscape report
- CHLORMADINONE ACETATE updates RSS · CI watch RSS
Frequently asked questions about CHLORMADINONE ACETATE
What is CHLORMADINONE ACETATE?
What development phase is CHLORMADINONE ACETATE in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing